4-(dimethylcarbamoyl)phenyl acetate | 20877-09-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 4-(dimethylcarbamoyl)phenyl acetate
• 英文别名: [4-(Dimethylcarbamoyl)phenyl] acetate
• CAS: 20877-09-2
• 化学式: C₁₁H₁₃NO₃
• 分子量: 207.229
• InChiKey: HTPZUNNFOJZKRY-UHFFFAOYSA-N

物化性质

• 沸点：
  348.0±25.0 °C(Predicted)
• 密度：
  1.136±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(dimethylcarbamoyl)phenyl acetate 在 potassium carbonate 作用下， 以 甲醇 为溶剂， 反应 5.0h， 以68%的产率得到4-羟基-N,N-二甲基苯甲酰胺
  参考文献：
  名称：

  Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines

  摘要：

  A new class of potent PI3K alpha inhibitors is identified based on aryl substituted morpholino-triazine scaffold. The identified compounds showed not only a high level of enzymatic and cellular potency in nanomolar range but also high oral bioavailability. The three lead molecules (based on their in vitro potency) when evaluated further for in vitro metabolic stability as well as pharmacokinetic profile led to the identification of 26, as a candidate for further development. The IC50 and EC50 value of 26 is 60 and 500 nM, respectively, for PI3Ka enzyme inhibitory activity and ovarian cancer (A2780) cell line. The identified lead also showed a high level of microsomal stability and minimal inhibition activity for CYP3A4, CYP2C19, and CYP2D6 at 10 mu M concentrations. The lead compound 26, demonstrated excellent oral bioavailability with an AUG of 5.2 mu M at a dose of 3 mpk in mice and found to be well tolerated in mice when dosed at 30 mpk BID for 5 days.

  DOI：

  10.1021/acsmedchemlett.5b00322
• 作为产物：
  描述：

  4-乙酰氧基苯甲酸 在 草酰氯 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 4-(dimethylcarbamoyl)phenyl acetate
  参考文献：
  名称：

  Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines

  摘要：

  A new class of potent PI3K alpha inhibitors is identified based on aryl substituted morpholino-triazine scaffold. The identified compounds showed not only a high level of enzymatic and cellular potency in nanomolar range but also high oral bioavailability. The three lead molecules (based on their in vitro potency) when evaluated further for in vitro metabolic stability as well as pharmacokinetic profile led to the identification of 26, as a candidate for further development. The IC50 and EC50 value of 26 is 60 and 500 nM, respectively, for PI3Ka enzyme inhibitory activity and ovarian cancer (A2780) cell line. The identified lead also showed a high level of microsomal stability and minimal inhibition activity for CYP3A4, CYP2C19, and CYP2D6 at 10 mu M concentrations. The lead compound 26, demonstrated excellent oral bioavailability with an AUG of 5.2 mu M at a dose of 3 mpk in mice and found to be well tolerated in mice when dosed at 30 mpk BID for 5 days.

  DOI：

  10.1021/acsmedchemlett.5b00322

文献信息

• Chemoselective Reduction of Tertiary Amides by 1,3-Diphenyl­disiloxane (DPDS)
  作者：Travis A. Hammerstad、Pooja V. Hegde、Courtney C. Aldrich、Kathleen J. Wang

  DOI：10.1055/a-1709-3426

  日期：2022.5

  A convenient procedure for the chemoselective reduction of tertiary amides at room temperature in the presence of air and moisture using 1,3-diphenyldisiloxane (DPDS) is developed. The reaction conditions tolerate a significant number of functional groups including esters, nitriles, secondary amides, carbamates, sulfoxides, sulfones, sulfonyl fluorides, halogens, aryl-nitro groups, and arylamines.

  开发了一种在室温下在空气和水分存在下使用 1,3-二苯基二硅氧烷 (DPDS) 化学选择性还原叔酰胺的简便方法。反应条件容许大量的官能团，包括酯、腈、仲酰胺、氨基甲酸酯、亚砜、砜、磺酰氟、卤素、芳基硝基和芳胺。报告的条件是迄今为止最温和的条件，并使用 EtOAc，这是一种优选的溶剂，因为它具有出色的安全性和较低的环境影响。易于设置和广泛的化学选择性使该方法对有机合成具有吸引力，结果进一步证明了 DPDS 作为选择性还原剂的实用性。
• NOVEL TRIAZINE COMPOUNDS
  申请人：Dugar Sundeep

  公开号：US20130303516A1

  公开（公告）日：2013-11-14

  The present invention relates to novel triazine compounds of formula (1), methods of their preparation, pharmaceutical compositions containing these compounds and the use of these compounds to treat proliferative disorders such as tumors and cancers and also other conditions and disorders related to or associated with dysregulation of PI3 Kinases, PI3 Kinase pathway, mTOR and/or the mTOR pathway.

  本发明涉及公式（1）的新型三嗪类化合物，其制备方法、含有这些化合物的药物组合物以及使用这些化合物治疗增殖性疾病，如肿瘤和癌症，以及与PI3激酶、PI3激酶途径、mTOR和/或mTOR途径失调相关或相关的其他状况和疾病。
• Revisiting the Mg/TMSCl/Dipolar Solvent System for Dearomatic Silylation of Aryl Carbonyl Compounds: Substrate Scope, Transformations, and Mechanistic Studies
  作者：Nan-Nan Li、Meng Li、Jia-Ni Gao、Zhong Zhang、Jian-Bo Xie

  DOI：10.1021/acs.joc.2c01178

  日期：2022.8.19

  demonstrated using the products as versatile substrate in various transformations. The detailed mechanism is presented with both control experimental analyses and theoretical calculations. An unusual five-coordinated silicon dianion intermediate is first proposed and described here. The selectivity is influenced by the relative rates of single electron reductions (the TMSCl/NMP adduct versus the substrate)

  芳烃衍生物的脱芳基甲硅烷基化是一个有趣的合成目标，它代表了 Birch 还原的优雅延伸，并产生具有进一步转化潜力的甲硅烷基化环己烯衍生物。在此，我们报告了一项关于芳基羰基化合物与 Mg 和 TMSCl/NMP 加合物脱芳基甲硅烷基化的系统研究。该协议显示了广泛的底物范围，包括烷基芳基酮、芳香酰胺、苯甲腈、叔-苯甲酸丁酯，甚至 2,2'-联吡啶。使用这些产品作为各种转化中的多功能底物，证明了合成效用。通过控制实验分析和理论计算提出了详细的机制。这里首先提出并描述了一种不寻常的五配位硅二阴离子中间体。选择性受单电子还原的相对速率（TMSCl/NMP 加合物与底物）和空间效应的影响。
• [EN] NOVEL TRIAZINE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS DE TRIAZINE
  申请人：SPHAERA PHARMA PTE LTD

  公开号：WO2014016849A9

  公开（公告）日：2014-03-13
• Copper-catalyzed amide bond formation from formamides and carboxylic acids
  作者：Hong-Qiang Liu、Jun Liu、Yang-Hui Zhang、Chang-Dong Shao、Jing-Xun Yu

  DOI：10.1016/j.cclet.2014.09.007

  日期：2015.1

  A highly efficient copper-catalyzed approach to form amide bonds from formamides and carboxylic acids was developed. This protocol shows broad substrate scopes and high yields in the presence of 1 mol% catalyst and 4.0 equiv. formamides. (C) 2014 Yang-Hui Zhang. Published by Elsevier B.V. on behalf of Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. All rights reserved.